The Food and Drug Administration has given Perrigo the green light to produce a store brand arthritis pain reliever that’s comparable to Voltaren.
The diclofenac sodium topical get 1% is over the counter for nonprescription use through the company’s prescription Rx-to-OTC switch process, and will be marketed under the retailer’s private brand as an alternative to GSK Consumer Healthcare's Voltaren Arthritis Pain.
Perrigo’s store brand option will launch later this year.
"This product approval and upcoming launch demonstrates the power and versatility of Perrigo's OTC self-care platform,” said CEO Murray Kessler. “The exceptional expertise demonstrated by our regulatory affairs team was evidenced through their impressive execution and record time in filing our submission and ultimately receiving approval. Our ability to successfully drive Rx-to-OTC switches differentiates Perrigo in the market place and is a perfect example of the Perrigo Advantage."